<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-CHC-1099776-O2</iati-identifier>
  <reporting-org ref="GB-CHC-1099776" type="21" xml:lang="EN">
   <narrative xml:lang="EN">Malaria Consortium</narrative>
  </reporting-org>
  <title xml:lang="EN">
   <narrative xml:lang="EN">Long Covid Research MC US</narrative>
  </title>
  <description type="1" xml:lang="EN">
   <narrative xml:lang="EN">Research to determine the burden of malaria and long-term complications following SARS-COV-2 infection and to assess health care pathways for the management of fever and other long-term complications following SARS-COV-2 infection</narrative>
  </description>
  <participating-org role="1" type="21" xml:lang="EN">
   <narrative xml:lang="EN">Malaria Consortium US Inc</narrative>
  </participating-org>
  <participating-org ref="GB-CHC-1099776" role="4" type="21" xml:lang="EN">
   <narrative xml:lang="EN">Malaria Consortium</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2022-03-15" type="2"></activity-date>
  <activity-date iso-date="2024-03-15" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Malaria Consortium</narrative>
   </organisation>
   <person-name>
    <narrative xml:lang="EN">Malaria Consortium</narrative>
   </person-name>
   <email>iati@malariaconsortium.org</email>
   <mailing-address>
    <narrative xml:lang="EN">The Green House, 244-254 Cambridge Heath Road, London, E2 9DA, United Kingdom</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="ET" percentage="33"></recipient-country>
  <recipient-country code="UG" percentage="67"></recipient-country>
  <sector code="12262" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Malaria control</narrative>
  </sector>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2022-03-15"></period-start>
   <period-end iso-date="2024-03-15"></period-end>
   <value currency="USD" value-date="2022-03-15">855000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2022-03-15"></transaction-date>
   <value currency="USD" value-date="2022-03-15">855000</value>
   <provider-org>
    <narrative xml:lang="EN">Malaria Consortium US Inc</narrative>
   </provider-org>
   <disbursement-channel code="2"></disbursement-channel>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-16"></transaction-date>
   <value currency="USD" value-date="2022-03-16">574960</value>
   <provider-org>
    <narrative xml:lang="EN">Malaria Consortium US Inc</narrative>
   </provider-org>
   <disbursement-channel code="2"></disbursement-channel>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="1"></transaction-type>
   <transaction-date iso-date="2022-03-18"></transaction-date>
   <value currency="USD" value-date="2022-03-18">281472</value>
   <provider-org>
    <narrative xml:lang="EN">Malaria Consortium US Inc</narrative>
   </provider-org>
   <disbursement-channel code="2"></disbursement-channel>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <related-activity ref="GB-CHC-1099776-O2-ET" type="2"></related-activity>
  <related-activity ref="GB-CHC-1099776-O2-UG" type="2"></related-activity>
 </iati-activity>
</iati-activities>
